These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 26002380)

  • 1. Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies.
    Bauer RA
    Drug Discov Today; 2015 Sep; 20(9):1061-73. PubMed ID: 26002380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can BDDCS illuminate targets in drug design?
    Bocci G; Benet LZ; Oprea TI
    Drug Discov Today; 2019 Dec; 24(12):2299-2306. PubMed ID: 31585170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Approaches to mitigate the risk of serious adverse reactions in covalent drug design.
    Baillie TA
    Expert Opin Drug Discov; 2021 Mar; 16(3):275-287. PubMed ID: 33006907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
    Stepan AF; Walker DP; Bauman J; Price DA; Baillie TA; Kalgutkar AS; Aleo MD
    Chem Res Toxicol; 2011 Sep; 24(9):1345-410. PubMed ID: 21702456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Achieving a low human dose for targeted covalent drugs: Pharmacokinetic and pharmacodynamic considerations on target characteristics and drug attributes.
    Yang Z
    Biopharm Drug Dispos; 2021 Apr; 42(4):150-159. PubMed ID: 33547681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is the pharmaceutical industry's preoccupation with the monotherapy drug model stifling the development of effective new drug therapies?
    Cock IE
    Inflammopharmacology; 2018 Jun; 26(3):861-879. PubMed ID: 29736688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics in Drug Discovery: An Exposure-Centred Approach to Optimising and Predicting Drug Efficacy and Safety.
    Reichel A; Lienau P
    Handb Exp Pharmacol; 2016; 232():235-60. PubMed ID: 26330260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The resurgence of covalent drugs.
    Singh J; Petter RC; Baillie TA; Whitty A
    Nat Rev Drug Discov; 2011 Apr; 10(4):307-17. PubMed ID: 21455239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug discovery for a new generation of covalent drugs.
    Kalgutkar AS; Dalvie DK
    Expert Opin Drug Discov; 2012 Jul; 7(7):561-81. PubMed ID: 22607458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The importance of drug-target residence time.
    Zhang R; Monsma F
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):488-96. PubMed ID: 19562645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefit-risk assessment: to quantify or not to quantify, that is the question.
    Yuan Z; Levitan B; Berlin JA
    Pharmacoepidemiol Drug Saf; 2011 Jun; 20(6):653-6. PubMed ID: 21538675
    [No Abstract]   [Full Text] [Related]  

  • 13. How pharmacogenomics (PG) are changing practice: implications for prescribers, their patients, and the healthcare system (PG series part I).
    Preskorn SH; Hatt CR
    J Psychiatr Pract; 2013 Mar; 19(2):142-9. PubMed ID: 23507814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Target identification of covalently binding drugs by activity-based protein profiling (ABPP).
    Pichler CM; Krysiak J; Breinbauer R
    Bioorg Med Chem; 2016 Aug; 24(15):3291-303. PubMed ID: 27085673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A modern in vivo pharmacokinetic paradigm: combining snapshot, rapid and full PK approaches to optimize and expedite early drug discovery.
    Li C; Liu B; Chang J; Groessl T; Zimmerman M; He YQ; Isbell J; Tuntland T
    Drug Discov Today; 2013 Jan; 18(1-2):71-8. PubMed ID: 22982770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binding kinetics and mechanism of action: toward the discovery and development of better and best in class drugs.
    Zhang R; Monsma F
    Expert Opin Drug Discov; 2010 Nov; 5(11):1023-9. PubMed ID: 22827742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Covalent Inhibition in Drug Discovery.
    Ghosh AK; Samanta I; Mondal A; Liu WR
    ChemMedChem; 2019 May; 14(9):889-906. PubMed ID: 30816012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serendipity in Cancer Drug Discovery: Rational or Coincidence?
    Prasad S; Gupta SC; Aggarwal BB
    Trends Pharmacol Sci; 2016 Jun; 37(6):435-450. PubMed ID: 27083322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo rat PK profiling in drug discovery: new challenges.
    Zonzini L; Bianchi F; Cesari N; Sartori M
    Expert Opin Drug Discov; 2010 Nov; 5(11):1031-7. PubMed ID: 22827743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Where do innovative drugs come from?
    Higgs G
    Drug Discov Today; 2011 Nov; 16(21-22):907-9. PubMed ID: 21889605
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.